The Penn State Hershey Cancer Institute will start a new pharmacogenomics research center thanks in part to $3.2 million federal funding, reports GenomeWeb.
The Penn State Center for Pharmacogenetics will house the cancer institute's samples and will be a resource and research center for translational studies focused on oncology drugs and prevention approaches.
Specimens from the Center for Pharmacogenetics repository will be used to study individual responses to therapeutic drugs and environmental toxins in efforts to identify gene variations that could serve as markers for these traits, and could then be used to develop or tailor treatments to individuals.
Original source: GenomeWebRead the full story here.